This technique is currently being used in Ovarian Cancer.
In collaboration with colleagues from the Walter Reed National Military Medical Center, the Inova Schar Cancer Institute and Frederick National Laboratory for Cancer Research the Radiomics group is working on the integration of proteomic and radiomic data into clinical decision models for patients with ovarian cancer. Over the last few years, the group has shown that radiomic metrics correlate with the response to chemotherapy and predict clinical endpoints such as progression-free survival and overall survival. In addition, it is well known that certain protein signatures of the tumour are associated with outcome. The group aims to build risk models that integrate both data streams to stratify patients according to risk for progression, thereby allowing for tailored therapy. In an exploratory analysis, they showed for the first time the association between proteomics and CT-based qualitative and texture features in ovarian cancer.
Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. Beer, L., et al., European Radiology, April 2020.
Summary: This study investigated the association between CT imaging traits and texture metrics with proteomic data in patients with high-grade serous ovarian cancer (HGSOC). It provides the first insights into the potential associations between standard-of-care CT imaging traits and texture measures of intra- and inter-site heterogeneity, and the abundance of several proteins.
Further information on the Integration of Proteomics and Radiomics project.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.